top of page
ONCOREDOX.jpg
Gal-Meister.jpg
Gal Meister
CEO

OncoRedox is developing a Point-of-care testing device for cancer detection based on ‘Redox-omics’ analysis of urine samples. The technology is based on biochemical electrodes detecting redox metabolic signature using an AI analysis model

stripBIG-01.jpg

PORTFOLIO

Product
icon-08.png

DEVICES

icon-09.png
icon-07.png

PHARMA & BIOTECH

icon-10.png
icon-06.png

PHARMA & BIOTECH

icon-11.png
bottom of page